Skip to main content
SpringerLink
Log in

Temsirolimus in patients with advanced renal cell carcinoma: an overview

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Treatment of patients with advanced renal cell carcinoma (RCC) has changed dramatically with the advent of targeted therapeutics. Temsirolimus, an inhibitor of mammalian target of rapamycin (mTOR), has proven beneficial in the treatment of advanced RCC with poor prognosis. The rationale for mTOR inhibitors in treatment of RCC, the pharmacokinetics and toxicities of temsirolimus, landmark clinical trials of temsirolimus in advanced RCC, and the indications for its use in the treatment of RCC are reviewed here. The status of temsirolimus in the rapidly evolving therapeutic landscape of advanced RCC is also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.

    Article  PubMed  Google Scholar 

  2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865–875.

    Article  PubMed  CAS  Google Scholar 

  3. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530–2540.

    PubMed  CAS  Google Scholar 

  4. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am. 2000;6(suppl 1.):S55–S57.

    PubMed  Google Scholar 

  5. Motzer RJ, Murphy BA, Bacik J, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol. 2000;18:2972–2980.

    PubMed  CAS  Google Scholar 

  6. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005;23:133–141.

    Article  PubMed  CAS  Google Scholar 

  7. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med. 1998;338:1272–1278.

    Article  PubMed  CAS  Google Scholar 

  8. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125–134.

    Article  PubMed  CAS  Google Scholar 

  9. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115–124.

    Article  PubMed  CAS  Google Scholar 

  10. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271–2281.

    Article  PubMed  CAS  Google Scholar 

  11. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol. 2008;26:5422–5428.

    Article  PubMed  CAS  Google Scholar 

  12. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial. Lancet. 2007;370:2103–2111.

    Article  PubMed  Google Scholar 

  13. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372:449–456.

    Article  PubMed  CAS  Google Scholar 

  14. Sehgal SN, Baker H, Vezina C. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization. J Antibiot (Tokyo). 1975;28:727–732.

    CAS  Google Scholar 

  15. Sehgal SN, Molnar-Kimber K, Ocain TD, Weichman BM. Rapamycin: a novel immunosuppressive macrolide. Med Res Rev. 1994;14:1–22.

    Article  PubMed  CAS  Google Scholar 

  16. Cafferkey R, Young PR, McLaughlin MM, et al. Dominant missense mutations in a novel yeast protein related to mammalian phosphatidylinositol 3-kinase and VPS34 abrogate rapamycin cytotoxicity. Mol Cell Biol. 1993;13:6012–6023.

    PubMed  CAS  Google Scholar 

  17. Heitman J, Movva NR, Hall MN. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science. 1991;253:905–909.

    Article  PubMed  CAS  Google Scholar 

  18. Brown EJ, Albers MW, Shin TB, et al. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756–758.

    Article  PubMed  CAS  Google Scholar 

  19. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem. 1998;273:14424–14429.

    Article  PubMed  CAS  Google Scholar 

  20. Shantz LM, Pegg AE. Overproduction of ornithine decarboxylase caused by relief of translational repression is associated with neoplastic transformation. Cancer Res. 1994;54:2313–2316.

    PubMed  CAS  Google Scholar 

  21. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell. 2002;110:163–175.

    Article  PubMed  CAS  Google Scholar 

  22. Frias MA, Thoreen CC, Jaffe JD, et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol. 2006;16:1865–1870.

    Article  PubMed  CAS  Google Scholar 

  23. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycininsensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol. 2004;14:1296–1302.

    Article  PubMed  CAS  Google Scholar 

  24. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098–1101.

    Article  PubMed  CAS  Google Scholar 

  25. Sarbassov DD, Ali SM, Sengupta S, et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell. 2006;22:159–168.

    Article  PubMed  CAS  Google Scholar 

  26. Linehan WM. Molecular targeting of VHL gene pathway in clear cell kidney cancer. J Urol. 2003;170:593–594.

    Article  PubMed  Google Scholar 

  27. Kondo K, Yao M, Yoshida M, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer. 2002;34:58–68.

    Article  PubMed  CAS  Google Scholar 

  28. Abraham RT. mTOR as a positive regulator of tumor cell responses to hypoxia. Curr Top Microbiol Immunol. 2004;279:299–319.

    PubMed  CAS  Google Scholar 

  29. Stadler WM. Targeted agents for the treatment of advanced renal cell carcinoma. Cancer. 2005;104:2323–2333.

    Article  PubMed  CAS  Google Scholar 

  30. Cantley LC, Neel BG. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci U S A. 1999;96:4240–4245.

    Article  PubMed  CAS  Google Scholar 

  31. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology. 2005;66(suppl.):1–9.

    Article  PubMed  Google Scholar 

  32. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A. 2001;98:10314–10319.

    Article  PubMed  CAS  Google Scholar 

  33. Podsypanina K, Lee RT, Politis C, et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/− mice. Proc Natl Acad Sci U S A. 2001;98:10320–10325.

    Article  PubMed  CAS  Google Scholar 

  34. Torisel (temsirolimus) package insert. Revised September 2008. Available at: www.wyeth.com/content/showlabelingasp?id=490. Accessed November 11, 2008.

  35. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909–918.

    Article  PubMed  CAS  Google Scholar 

  36. Boni J, Abbas R, Leister C, et al. Disposition of desipramine, a sensitive cytochrome P450 2D6 substrate, when coadministered with intravenous temsirolimus. Cancer Chemother Pharmacol. In press.

  37. Kuhn JG, Chang SM, Wen PY, et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007;13:7401–7406.

    Article  PubMed  CAS  Google Scholar 

  38. Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L. Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome p450-inducing medications. J Clin Pharmacol. 2007;47:1430–439.

    Article  PubMed  CAS  Google Scholar 

  39. Boni JP, Leister C, Bender G, et al. Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther. 2005;77:76–89.

    Article  PubMed  CAS  Google Scholar 

  40. Lunardi G, Vannozzi MO, Armirotti A, Nicodemo M, Venturini M, Cavallini L. Temsirolimus in patients with renal cancer on hemodialysis. J Clin Oncol. 2008;26:5652–5653.

    Article  PubMed  Google Scholar 

  41. Raymond E, Alexandre J, Faivre S, et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol. 2004;22:2336–2347.

    Article  PubMed  CAS  Google Scholar 

  42. Motzer RJ, Hudes GR, Curti BD, et al. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol. 2007;25:3958–3964.

    Article  PubMed  CAS  Google Scholar 

  43. Huffman TA, Mothe-Satney I, Lawrence JC Jr. Insulin-stimulated phosphorylation of lipin mediated by the mammalian target of rapamycin. Proc Natl Acad Sci U S A. 2002;99:1047–1052.

    Article  PubMed  CAS  Google Scholar 

  44. Taha C, Liu Z, Jin J, Al-Hasani H, Sonenberg N, Klip A. Opposite translational control of GLUT1 and GLUT4 glucose transporter mRNAs in response to insulin. Role of mammalian target of rapamycin, protein kinase b, and phosphatidylinositol 3-kinase in GLUT1 mRNA translation. J Biol Chem. 1999;274:33085–33091.

    Article  PubMed  CAS  Google Scholar 

  45. Duran I, Siu LL, Oza AM, et al. Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus. Eur J Cancer. 2006;42:1875–1880.

    Article  PubMed  CAS  Google Scholar 

  46. Pham PT, Pham PC, Danovitch GM, et al. Sirolimusassociated pulmonary toxicity. Transplantation. 2004;77:1215–1220.

    Article  PubMed  CAS  Google Scholar 

  47. Figlin RA, Hutson TE, Tomczak P, et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol. 2008;26(suppl.). Abstract 5024.

    Google Scholar 

  48. Study comparing bevacizumab + temsirolimus vs bevacizumab + interferon-alfa in advanced renal cell carcinoma subjects. ClinicalTrials.gov web site. Available at: http://clinicaltrials.gov/ct2/show/NCT00631371?term=bevacizumab+temsirolimus+IFN&rank=1. Accessed December 2008.

  49. Temsirolimus versus sorafenib as second-line therapy in patients with advanced RCC who have failed first-line sunitinib. ClinicalTrials.gov web site. Available at: http://clinicaltrials.gov/ct2/show/NC T00474786?term=temsirolimus+sorafenib+sunitini b&rank=1. Accessed December 2008.

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Department of Medicine, University of Washington/Fred Hutchinson Cancer Research Center, 825 Eastlake Ave E, Mailstop G4-830, Seattle, WA, 98109, USA

    Shailender Bhatia

  2. University of Washington, Seattle, WA, USA Fred Hutchinson Cancer Research Center, Seattle, WA, USA

    John A. Thompson

Authors
  1. Shailender Bhatia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John A. Thompson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Shailender Bhatia.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bhatia, S., Thompson, J.A. Temsirolimus in patients with advanced renal cell carcinoma: an overview. Adv Therapy 26, 55–67 (2009). https://doi.org/10.1007/s12325-008-0138-3

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-008-0138-3

Keywords

Search

Navigation